Imagine bacteria have a 'cloaking device' that hides them from your immune system. This project created a vaccine that disables that cloaking device, allowing your body to see and kill the bacteria naturally. Instead of attacking the bacteria directly—which often makes them evolve and become stronger—it simply removes their shield. This works across five different types of dangerous bacteria at once.
Antibiotics are becoming ineffective against 'superbugs,' and current vaccines only cover a small fraction of bacterial strains. This creates a massive public health risk and a $30 billion annual financial burden on Western health systems.
A multivalent vaccine (PNV) that blocks the GAPDH immunosuppressive protein common to five deadly bacteria.
If you are a vaccine manufacturer dealing with the failure of traditional vaccines to cover all serotypes—where current options only cover 20 of 95 known strains—this project developed PNV that provides full coverage against all serotypes of five deadly bacteria.
If you are a health agency dealing with the $30 billion annual cost of AMR to health systems, this project developed a preventive immunotherapy that stops the progression of AMR and avoids millions of deaths globally.
If you are a biotech firm dealing with the fact that 4 of the 5 most deadly bacteria are now highly resistant to antibiotics, this project developed a method to block the GAPDH protein to restore the host's natural immune response.
The technology is patented under WO/2015/189422. Based on available project data, the intellectual property covers the discovery of the GAPDH-blocking mechanism.
Based on available project data, the specific unit cost or market price of the PNV vaccine is not provided.
Based on available project data, the project has successfully undergone preclinical trials, but specific industrial scaling metrics are not detailed.
It serves as a preventive immunotherapy that allows the immune system to control infections without creating the pressure that induces antibiotic resistance.
The project period runs from 2023-01-01 to 2026-11-30, suggesting the development and validation phase is currently active.
The project is led by a single SME, IMMUNETHEP from Portugal, representing 100% of the consortium. This lean structure indicates a high level of agility and direct control over the IP, though it lacks the diversified academic or large-scale industrial partnerships typically seen in larger EU consortia.
Contact IMMUNETHEP (PT) regarding the PNV vaccine patent WO/2015/189422
Contact us to explore licensing opportunities for this multivalent AMR vaccine.
